Neutrophils and their role in lung cancer treatment response
Official title: Neutrophil derived proteinases abolish the IFNG signature in NSCLC
Funded at Fred Hutchinson Cancer Center · NIH-10884281 · Data updated 2026-11-12
This study is looking at how certain white blood cells called neutrophils might make it harder for cancer treatments, known as immune checkpoint inhibitors, to work well in people with non-small cell lung cancer, and the researchers hope to find ways to improve these treatments by understanding how neutrophils affect the immune response to tumors.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | July 7, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $555,585 |
| NIH project number | 5R01CA282465-02 |
| Project ID | NIH-10884281 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with non-small cell lung cancer who are considering or currently undergoing immune checkpoint inhibitor therapy.
✕Less likely to help
Patients with other types of lung cancer or those who are not eligible for immunotherapy may not benefit from this research.
What this research studies
This research investigates how neutrophils in non-small cell lung cancer (NSCLC) may hinder the effectiveness of immune checkpoint inhibitors, which are treatments that help the immune system fight cancer. The researchers will explore how proteins released by neutrophils can degrade important signals that attract immune cells to tumors, potentially preventing a strong immune response. By using advanced models that mimic tumor environments, they aim to understand the mechanisms behind this process and identify new targets for improving treatment outcomes for patients with NSCLC.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for NSCLC patients, enhancing their response to immunotherapy.
How similar studies have gone: Previous research has shown that targeting immune cell interactions in tumors can improve treatment responses, suggesting that this approach may also yield significant insights.
Where this research is happening
-
Fred Hutchinson Cancer Center
Seattle, United States Active
Researchers
- Principal investigator: Houghton, a Mcgarry — Fred Hutchinson Cancer Center
- Study coordinator: Houghton, a Mcgarry
Related research
Other NIH-funded projects on the same topics.
-
7-marker protein test to predict NSCLC response to anti-PD-1 therapy
A Johns Hopkins team is testing a 7-marker protein test to help predict which advanced NSCLC patients will respond to anti-PD-1 therapy.
-
Barcoded tumor sequencing to map radiation-triggered immune effects in lung cancer
This project uses barcoded tumor models and sequencing to uncover how adding radiation to immunotherapy might spark whole-body immune attacks against non-small cell lung cancer.
-
Targeting the cancer-friendly secretory system in a common lung cancer cancer subtype
A study tests new ways to block the secretory system inside tumor cells to stop growth and spread in a major subtype of non-small cell lung cancer.
-
Predicting outcomes and side effects in stage III NSCLC with AI-driven imaging
A multimodal AI approach uses chest CT and tissue images to forecast how patients with unresectable stage III NSCLC will respond to durvalumab after chemoradiotherapy and who might develop pneumonitis.
-
ATM kinase as a target to help NSCLC with brain metastases respond to treatment
A study from Yale University tests whether blocking ATM kinase can delay or overcome treatment resistance in people with advanced non-small cell lung cancer that has spread to the brain and other organs.
-
Understanding how cancer-supportive tissue affects resistance to ALK and KRAS therapies
A research team will study how the tumor’s surrounding tissue changes as cancer cells become resistant to ALK and KRAS-targeted treatments, aiming to find better combination strategies for long-lasting remission.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.